Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- The Boy, the Jothishi, and the Backward-Walking Planets: How Two People Built True Vedic Astrology AIAbout RetroGrade RetroGrade is an AI-powered Vedic Astrology platform developed under Jothishi. It combines classical Jyotisha techniques — dashas, varga charts, yogas, planetary strengths and avasthas — with modern LLM and RAG technology.
- MicrosoftHow two young Indonesians are building digital careers through AI and cloudCompanies: MicrosoftThe post How two young Indonesians are building digital careers through AI and cloud appeared first on Source.
- OpenAIHow HSP GRUPPE builds AI capabilities for tax advisoryCompanies: OpenAIDiscover how HSP GRUPPE uses ChatGPT Enterprise to boost productivity, improve work quality, and create more capacity for tax advisory and client service.
- Samsung[Infographic] [Galaxy Unpacked July 2026] Samsung Members Stars Share Their Favorite Features of the New Galaxy DevicesCompanies: Samsung ElectronicsFrom July 22 to 24, Samsung Electronics brought together 51 Samsung Members Stars from 17 countries for Galaxy Community Connect July 2026 in London. Samsung Members Stars are highly engaged Galaxy users who consistently create high-quality content and actively contribute to the Samsung Members platform. Participants attended Galaxy Unpacked July 2026 and explored various parts […]
- Cision Ltd.Cision Wins 2026 MarTech Breakthrough Awards for Social Listening, Press Release Distribution, and AEOBrandwatch named "Social Listening Solution of the Year," while PR Newswire secures top honors for "Press Release Distribution Company of the Year" and "AEO Platform of the Year" Cision, a global leader in consumer and media intelligence, today announced that two of its brands, Brandwatch and PR Newswire, have together earned three major category honors in the 2026 MarTech Breakthrough Awards. The a
- Oracleオラクル、数千社のエンタープライズ・アプリケーションのお客様にGeminiモデルを提供へCompanies: Oracle CorporationAustin, Texas and Sunnyvale, California—Jul 30, 2026 Oracle and Google Cloud have expanded their partnership to bring Google’s Gemini models to Oracle’s extensive portfolio of enterprise applications. The partnership builds on customers’ existing access to Gemini models through Oracle Cloud Infrastructure (OCI) Enterprise AI and is planned to make Gemini models available in Oracle AI Agent Studio for Fusion Applicati
- IBMIBM Introduces Apptio AI Value & ROI to Close the Gap Between AI Spend and Business ResultsCompanies: IBMNew release gives technology and finance executives a single view of token spend, cost, and the business outcomes AI investments actually produce Key facts IBM Apptio AI Value & ROI connects AI spending, including token costs, to measurable business outcomes. Technology and finance executives can track AI initiatives across revenue, cost, speed, productivity and risk. IBM Apptio AI Value & ROI is available in public
- SalesforceMissionforce National Security Unveils IL5-Authorized AI Agents and Apps to Drive Decision Advantage, Readiness, and Enhanced Warfighter SupportCompanies: SalesforceWith new IL5 authorization, Agentforce 360 — Salesforce’s full portfolio of AI agents, data capabilities, and apps — is now embedded into the Missionforce National Security platform. The Department of War (DOW) can now deploy autonomous AI agents to streamline defense logistics, fast-track recruit onboarding and training, alleviate administrative burdens for military families, and transform […]
- Oracle오라클, 엔터프라이즈 애플리케이션 전반에 제미나이 모델 지원한다Companies: Oracle CorporationAustin, Texas and Sunnyvale, California—Jul 30, 2026 Oracle and Google Cloud have expanded their partnership to bring Google’s Gemini models to Oracle’s extensive portfolio of enterprise applications. The partnership builds on customers’ existing access to Gemini models through Oracle Cloud Infrastructure (OCI) Enterprise AI and is planned to make Gemini models available in Oracle AI Agent Studio for Fusion Applicati
- Oracle美诺酒店集团借助 Oracle Cloud 加速全球数字化转型Companies: Oracle CorporationAustin, Texas and Bangkok, Thailand—Aug 4, 2026 Minor Hotels has successfully rolled out Oracle OPERA Cloud across 106 of its hotels, resorts, and branded residences in 59 countries. This milestone marks a significant step in Minor’s digital transformation strategy and commitment to elevating guest and associate experiences across its portfolio. The hotel chain also added Oracle OPERA Cloud Central , further strength
- SAPHow Salling Group Uses SAP and AI to Improve Everyday RetailCompanies: SAPThe European retailer is positioned to apply AI at scale with its SAP Cloud ERP backbone.
- BayerBayer operationally on track, decisive progress on strategic prioritiesCompanies: BayerThe Bayer Group continued to make headway in the second quarter of 2026, capping off a successful first half of the year. “Operationally, we’re well on track to achieve our full-year outlook,” CEO Bill Anderson said when presenting the company’s Half-Year Financial Report on Tuesday. All three divisions are on target, he noted. Bayer has also made decisive progress on its long-term strategic priorities, Anderson emphasized. The landmark US Supreme Court ruling in the Durnell case is one such example, he said, adding that it puts Bayer in a stronger position for the proposed class settlement agreement. “Overall, our containment strategy is in a strong place, with some important milestones ahead,” Anderson explained. Bayer is also advancing its other strategic priorities, Anderson said, pointing to progress in rejuvenating the Pharmaceuticals pipeline and executing the Five-Year Framework to improve profitability at Crop Science. In addition, Bayer’s lean, entrepreneurial operating model is driving efficiency gains across the entire Group, while also positioning the company well to effectively capitalize on the opportunities of artificial intelligence, he noted. “Over the past two and a half years, we’ve progressed in each of these areas. Each of them has demanded intense focus – and it’s imperative that we maintain that focus,” Anderson emphasized. “We’re concentrating on delivering our commitments and ensuring the best future for Bayer.” Dr. Judith Hartmann, who took over the CFO role in June, shared her perspective. “I am excited to be part of the team driving Bayer forward at such an important time in its journey. While we’ve delivered strong strategic and financial progress, including meaningful steps on our balance sheet, important opportunities remain ahead of us. Bayer benefits from a powerful innovation engine and growth prospects across all three businesses. Our financial priorities are clear: to further strengthen the balance sheet, enhance productivity and improve cash generation, while continuing to invest behind growth and creating sustainable value,” Hartmann said. Sales and EBITDA before special items up against prior year Group sales came in at 10.872 billion euros in the second quarter of 2026, up 2.2 percent on a currency- and portfolio-adjusted basis (Fx & portfolio adj.). There was a negative currency effect of 63 million euros (Q2 2025: 550 million euros). EBITDA before special items increased by 1.9 percent to 2.144 billion euros, and included a negative currency effect of 70 million euros (Q2 2025: 184 million euros). EBIT amounted to 827 million euros (Q2 2025: 13 million euros) after net special charges of 172 million euros (Q2 2025: 981 million euros) that were primarily attributable to litigation-related expenses. Net income came in at 219 million euros (Q2 2025: minus 199 million euros). Core earnings per share decreased by 16.7 percent to 0.95 euros, with the improvement in earnings in the Crop Science Division only partially offsetting a normalization in tax expense and lower earnings in the Reconciliation. Free cash flow amounted to minus 371 million euros (Q2 2025: 125 million euros), partly due to higher payments to resolve litigation. Net financial debt came in at 33.647 billion euros as of June 30, 2026, representing a 3.5 percent increase against March 31, 2026, and a 1.1 percent rise from a year-on-year perspective. Crop Science: Topline growth and efficiencies in cost of goods sold drive higher earnings In the agricultural business (Crop Science), sales increased by 3.5 percent (Fx & portfolio adj.) to 4.910 billion euros. Business was up at Soybean Seed & Traits and Cotton Seed following the return of the dicamba label in the United States, with gains of 16.9 and 69.2 percent (Fx & portfolio adj.), respectively. By contrast, sales at Corn Seed & Traits were down 2.5 percent (Fx & portfolio adj.), with substantial gains in Europe/Middle East/Africa and Asia/Pacific only partially offsetting lower volumes in North America, where business was impacted by volume phasing into the first quarter. In the Crop Protection business, growth was primarily driven by the division’s glyphosate-based herbicides. Sales of these products rose by 12.6 percent (Fx & portfolio adj.) fueled by higher volumes and prices, especially in Europe/Middle East/Africa. The Insecticides business recorded a 15.9 percent (Fx & portfolio adj.) increase in sales that was mainly attributable to higher volumes and prices in Europe/Middle East/Africa and Asia/Pacific. EBITDA before special items at Crop Science advanced by 30.2 percent to 902 million euros. The increase in earnings was largely fueled by high-margin topline growth as well as a decline in the cost of goods sold that was driven by efficiency programs, as the division continues implementation of its Five-Year Framework. The EBITDA margin before special items increased by 3.9 percentage points to 18.4 percent. Pharmaceuticals: Continued growth momentum for Nubeqa™ and Kerendia™ Sales of prescription medicines (Pharmaceuticals) came in at 4.458 billion euros, in line with the prior year (Fx & portfolio adj. plus 0.8 percent). The division again registered significant gains for its cancer drug Nubeqa™, as well as for Kerendia™, its product for the treatment of chronic kidney disease and heart failure. Nubeqa™ sales advanced by 63.9 percent (Fx & portfolio adj.), mainly driven by volume growth in the United States and Europe, while the 82.9 percent (Fx & portfolio adj.) rise in Kerendia™ sales was largely fueled by higher volumes in the United States and China. The Mirena™ product family also delivered very strong topline performance, especially in the United States, with global sales rising 9.0 percent (Fx & portfolio adj.). In the Radiology business, the division recorded gains of 26.8 and 8.1 percent (Fx & portfolio adj.) for Ultravist™ and CT Fluid Delivery, respectively. Business benefited from higher volumes, while prices remained stable. By contrast, Xarelto™ and Eylea™ sales were down significantly, as anticipated. After encountering headwinds from patent expirations, the oral anticoagulant posted a decline of 42.4 percent (Fx & portfolio adj.), while business with the ophthalmology drug decreased 32.8 percent (Fx & portfolio adj.). The Eylea™ 8 mg formulation offering extended treatment intervals accounted for around 55 percent of overall Eylea™ sales. EBITDA before special items at Pharmaceuticals decreased by 3.6 percent to 1.055 billion euros. The decline in earnings was primarily attributable to the division channeling higher investments toward marketing its growth products Lynkuet™ (for the hormone-free treatment of menopause symptoms), Nubeqa™ and Kerendia™. In addition, the prior-year quarter had benefited from proceeds from the sale of non-core businesses. By contrast, earnings benefited from a reduction in allocations to provisions for the Group-wide short-term incentive (STI) program, as well as an inventory write-back. The EBITDA margin before special items decreased by 0.8 percentage points to 23.7 percent. Consumer Health sales up in almost all categories and regions Following a strong first quarter, sales of self-care products (Consumer Health) increased by 1.5 percent (Fx & portfolio adj.) to 1.445 billion euros. Business was up in almost all categories, with Digestive Health delivering the strongest growth, at 9.4 percent (Fx & portfolio adj.). By contrast, sales in the Allergy & Cold category were down 8.0 percent (Fx & portfolio adj.) due to soft seasonality. Regionally, the division continued to face headwinds from a weak market environment in the United States, while business was up year on year in Europe/Middle East/Africa, Latin America and Asia/Pacific. EBITDA before special items at Consumer Health decreased by 3.6 percent to 319 million euros. The decline in earnings was mainly due to an increase in the cost of goods sold and unfavorable product mix effects. These headwinds were only partially offset by the division’s continuous cost and price management efforts. The EBITDA margin before special items declined by 1.1 percentage points to 22.1 percent. Group sales and earnings up in first half of the year In the first six months of 2026, Group sales rose by 3.3 percent (Fx & portfolio adj.) to 24.277 billion euros. EBITDA before special items advanced 6.6 percent to 6.597 billion euros, while core earnings per share increased 3.4 percent to 3.66 euros. Currency-adjusted Group outlook confirmed Bayer has affirmed its currency-adjusted Group guidance for full-year 2026 for all metrics except net financial debt, which it now expects to come in lower than originally projected, at 29 to 30 billion euros (previous forecast: 32 to 33 billion euros). The revised guidance for this KPI reflects the already announced agreement with Apollo-managed funds and affiliates. They will obtain a minority, non-controlling stake in a newly established entity holding Bayer’s long-acting reversible contraceptives (LARC) business in exchange for a €3.0 billion capital contribution. In addition, applying the closing rates as of June 30, 2026, instead of March 31, 2026, results in the following changes: Group sales are now expected to come in at 44.7 to 46.7 billion euros (44.5 to 46.5 billion euros at previous closing rates), and core EPS at 4.20 to 4.70 euros (4.10 to 4.60 euros at previous closing rates). Notes: The following tables contain the key data for the Bayer Group and its divisions for the second quarter and the first six months of 2026. The full Half-Year Financial Report is available online at: www.bayer.com/halfyearreport. There is also a digital version available. The speech given by Bill Anderson and Dr. Judith Hartmann to the media will be available online from around 9 a.m. CEST at: www.bayer.com/speeches Live broadcast of the Media Update from around 9 a.m. CEST and recording available from around 12 p.m. CEST at: www.bayer.com/live-mc Additional information for investors, including presentation charts, and access to the live broadcast of the Investor Video Call (from around 2 p.m. CEST) and recording (from around 6 p.m. CEST) available at: www.bayer.com/live-ic Print-quality photos can be found online at: www.bayer.com/photo-footage You can find FAQ on this topic here. Find more information at www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.